The European drug's regulator Friday advised against approving Amgen's new cancer drug Vectibix for use in advanced colon cancer, saying its benefits didn't outweigh its risks.
The London-based European Medicines Agency said its Committee for Medicinal Products for Human Use was concerned that there wasn't sufficient evidence to show a benefit of Vectibix, due to the way the main clinical study submitted was designed.
WSJ
No comments:
Post a Comment